{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T00:20:35Z","timestamp":1795134035214,"version":"4.10.3"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T00:00:00Z","timestamp":1647388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T00:00:00Z","timestamp":1647388800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Patients with unresectable intrahepatic cholangiocarcinoma (iCCA) have poor survival. This systematic review describes the survival outcomes of hepatic arterial infusion pump (HAIP) chemotherapy with floxuridine for patients with unresectable iCCA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>A literature search was conducted using the electronic databases PubMed, Medline (Ovid), Embase, Web of Science, Google Scholar, and Cochrane to find studies that reported data on the survival of patients with unresectable iCCA treated with HAIP chemotherapy using floxuridine. The quality of the studies was assessed using the Newcastle\u2013Ottawa quality assessment Scale (NOS). Overall survival (OS) was the primary outcome measure, and progression-free survival (PFS), response rates, resection rates, and toxicity were defined as secondary outcome measures.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>After removing duplicates, 661 publications were assessed, of which nine studies, representing a total of 478 patients, met the inclusion criteria. Three out of nine studies were phase II clinical trials, one study was a prospective dose-escalation study, and the remaining five studies were retrospective cohort studies. After accounting for overlapping cohorts, 154 unique patients were included for pooled analysis. The weighted median OS of patients with unresectable iCCA treated with HAIP chemotherapy with floxuridine was 29.0 months (range 25.0\u201339 months). The pooled 1-, 2-, 3-, and 5-year OS were 86.4, 55.5, 39.5, and 9.7%, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>HAIP chemotherapy with floxuridine for patients with unresectable iCCA was associated with a 3-year OS of 39.5%, which is favorable compared with systemic chemotherapy for which no 3-year survivors were reported in the Advanced Biliary Cancer (ABC) trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1245\/s10434-022-11439-x","type":"journal-article","created":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T11:04:45Z","timestamp":1647428685000},"page":"5528-5538","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Hepatic Arterial Infusion Pump Chemotherapy for Unresectable Intrahepatic Cholangiocarcinoma: A Systematic Review and Meta-Analysis"],"prefix":"10.1245","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6503-4525","authenticated-orcid":false,"given":"Jessica J.","family":"Holster","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marouan","family":"El Hassnaoui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stijn","family":"Franssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan N. M.","family":"IJzermans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen","family":"de Jonge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca","family":"Mostert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wojciech G.","family":"Polak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roeland F.","family":"de Wilde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjolein Y. V.","family":"Homs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bas","family":"Groot Koerkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,16]]},"reference":[{"issue":"6","key":"11439_CR1","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1016\/S0168-8278(02)00297-0","volume":"37","author":"SA Khan","year":"2002","unstructured":"Khan SA, Taylor-Robinson SD, Toledano MB, Beck A, Elliott P, Thomas HC. Changing international trends in mortality rates for liver, biliary and pancreatic tumours. J Hepatol. 2002;37(6):806\u201313.","journal-title":"J Hepatol."},{"key":"11439_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-2-10","author":"T Patel","year":"2002","unstructured":"Patel T. Worldwide trends in mortality from biliary tract malignancies. BMC Cancer. 2002. https:\/\/doi.org\/10.1186\/1471-2407-2-10.","journal-title":"BMC Cancer"},{"issue":"4","key":"11439_CR3","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/j.suc.2010.04.011","volume":"90","author":"GA Poultsides","year":"2010","unstructured":"Poultsides GA, Zhu AX, Choti MA, Pawlik TM. Intrahepatic cholangiocarcinoma. Surg Clin North Am. 2010;90(4):817\u201337.","journal-title":"Surg Clin North Am."},{"issue":"9","key":"11439_CR4","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1038\/nrgastro.2011.131","volume":"8","author":"B Blechacz","year":"2011","unstructured":"Blechacz B, Komuta M, Roskams T, Gores GJ. Clinical diagnosis and staging of cholangiocarcinoma. Nat Rev Gastroenterol Hepatol. 2011;8(9):512\u201322.","journal-title":"Nat Rev Gastroenterol Hepatol."},{"issue":"2","key":"11439_CR5","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1245\/s10434-007-9627-x","volume":"15","author":"JC Tan","year":"2008","unstructured":"Tan JC, Coburn NG, Baxter NN, Kiss A, Law CH. Surgical management of intrahepatic cholangiocarcinoma\u2013a population-based study. Ann Surg Oncol. 2008;15(2):600\u20138.","journal-title":"Ann Surg Oncol."},{"issue":"4","key":"11439_CR6","doi-asserted-by":"publisher","first-page":"298","DOI":"10.5009\/gnl.2009.3.4.298","volume":"3","author":"J Park","year":"2009","unstructured":"Park J, Kim MH, Kim KP, et al. Natural history and prognostic factors of advanced cholangiocarcinoma without surgery, chemotherapy, or radiotherapy: a large-scale observational study. Gut Liver. 2009;3(4):298\u2013305.","journal-title":"Gut Liver."},{"issue":"8","key":"11439_CR7","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1002\/cncr.30488","volume":"123","author":"S Yamashita","year":"2017","unstructured":"Yamashita S, Koay EJ, Passot G, et al. Local therapy reduces the risk of liver failure and improves survival in patients with intrahepatic cholangiocarcinoma: a comprehensive analysis of 362 consecutive patients. Cancer. 2017;123(8):1354\u201362.","journal-title":"Cancer."},{"issue":"14","key":"11439_CR8","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273\u201381.","journal-title":"N Engl J Med."},{"issue":"2","key":"11439_CR9","first-page":"200","volume":"112","author":"A Lamarca","year":"2020","unstructured":"Lamarca A, Ross P, Wasan HS, et al. Advanced intrahepatic cholangiocarcinoma: post hoc analysis of the ABC-01, -02, and -03 clinical trials. J Natl Cancer Inst. 2020;112(2):200\u201310.","journal-title":"J Natl Cancer Inst."},{"issue":"4","key":"11439_CR10","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1002\/1097-0142(19920215)69:4<920::AID-CNCR2820690414>3.0.CO;2-Y","volume":"69","author":"OT Atiq","year":"1992","unstructured":"Atiq OT, Kemeny N, Niedzwiecki D, Botet J. Treatment of unresectable primary liver cancer with intrahepatic fluorodeoxyuridine and mitomycin C through an implantable pump. Cancer. 1992;69(4):920\u20134.","journal-title":"Cancer."},{"issue":"5","key":"11439_CR11","first-page":"969","volume":"30","author":"C Breedis","year":"1954","unstructured":"Breedis C, Young G. The blood supply of neoplasms in the liver. Am J Pathol. 1954;30(5):969\u201377.","journal-title":"Am J Pathol."},{"issue":"11","key":"11439_CR12","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1200\/JCO.1987.5.11.1836","volume":"5","author":"ER Sigurdson","year":"1987","unstructured":"Sigurdson ER, Ridge JA, Kemeny N, Daly JM. Tumor and liver drug uptake following hepatic artery and portal vein infusion. J Clin Oncol. 1987;5(11):1836\u201340.","journal-title":"J Clin Oncol."},{"issue":"11 Pt 1","key":"11439_CR13","first-page":"3784","volume":"38","author":"WD Ensminger","year":"1978","unstructured":"Ensminger WD, Rosowsky A, Raso V, et al. A clinical-pharmacological evaluation of hepatic arterial infusions of 5-fluoro-2\u2019-deoxyuridine and 5-fluorouracil. Cancer Res. 1978;38(11 Pt 1):3784\u201392.","journal-title":"Cancer Res."},{"key":"11439_CR14","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"issue":"2","key":"11439_CR15","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347.","journal-title":"Eur J Cancer"},{"issue":"3","key":"11439_CR16","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors European organization for research and treatment of cancer national cancer institute of the United States national cancer institute of canada. J Natl Cancer Inst. 2000;92(3):205\u201316.","journal-title":"J Natl Cancer Inst"},{"issue":"9","key":"11439_CR17","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","volume":"25","author":"A Stang","year":"2010","unstructured":"Stang A. Critical evaluation of the newcastle-ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603\u20135.","journal-title":"Eur J Epidemiol."},{"issue":"8","key":"11439_CR18","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1002\/bjs.10870","volume":"105","author":"E Versteijne","year":"2018","unstructured":"Versteijne E, Vogel JA, Besselink MG, et al. Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer. Br J Surg. 2018;105(8):946\u201358.","journal-title":"Br J Surg."},{"issue":"4","key":"11439_CR19","doi-asserted-by":"publisher","first-page":"e1000267","DOI":"10.1371\/journal.pmed.1000267","volume":"7","author":"S Gillen","year":"2010","unstructured":"Gillen S, Schuster T, Meyer Zum B\u00fcschenfelde C, Friess H, Kleeff J. Preoperative\/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med. 2010;7(4):e1000267.","journal-title":"PLoS Med"},{"issue":"3","key":"11439_CR20","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177\u201388.","journal-title":"Control Clin Trials."},{"issue":"7109","key":"11439_CR21","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629\u201334.","journal-title":"BMJ."},{"key":"11439_CR22","doi-asserted-by":"publisher","first-page":"d4002","DOI":"10.1136\/bmj.d4002","volume":"343","author":"JA Sterne","year":"2011","unstructured":"Sterne JA, Sutton AJ, Ioannidis JP, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ. 2011;343:d4002.","journal-title":"BMJ"},{"issue":"1","key":"11439_CR23","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1097\/SLA.0b013e318176c4d3","volume":"248","author":"I Endo","year":"2008","unstructured":"Endo I, Gonen M, Yopp AC, et al. Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. Ann Surg. 2008;248(1):84\u201396.","journal-title":"Ann Surg."},{"issue":"8","key":"11439_CR24","doi-asserted-by":"publisher","first-page":"2675","DOI":"10.1245\/s10434-014-3649-y","volume":"21","author":"IT Konstantinidis","year":"2014","unstructured":"Konstantinidis IT, Do RK, Gultekin DH, et al. Regional chemotherapy for unresectable intrahepatic cholangiocarcinoma: a potential role for dynamic magnetic resonance imaging as an imaging biomarker and a survival update from two prospective clinical trials. Ann Surg Oncol. 2014;21(8):2675\u201383.","journal-title":"Ann Surg Oncol."},{"issue":"5","key":"11439_CR25","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1002\/cncr.29824","volume":"122","author":"IT Konstantinidis","year":"2016","unstructured":"Konstantinidis IT, Groot Koerkamp B, Do RK, et al. Unresectable intrahepatic cholangiocarcinoma: systemic plus hepatic arterial infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone. Cancer. 2016;122(5):758\u201365.","journal-title":"Cancer."},{"issue":"1","key":"11439_CR26","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1001\/jamaoncol.2019.3718","volume":"6","author":"A Cercek","year":"2020","unstructured":"Cercek A, Boerner T, Tan BR, et al. Assessment of hepatic arterial infusion of floxuridine in combination with systemic gemcitabine and oxaliplatin in patients with unresectable intrahepatic cholangiocarcinoma: a phase 2 clinical trial. JAMA Oncol. 2020;6(1):60\u20137.","journal-title":"JAMA Oncol."},{"issue":"1","key":"11439_CR27","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1245\/s10434-017-6110-1","volume":"25","author":"GP Wright","year":"2018","unstructured":"Wright GP, Perkins S, Jones H, et al. Surgical resection does not improve survival in multifocal intrahepatic cholangiocarcinoma: a comparison of surgical resection with intra-arterial therapies. Ann Surg Oncol. 2018;25(1):83\u201390.","journal-title":"Ann Surg Oncol."},{"issue":"14","key":"11439_CR28","doi-asserted-by":"publisher","first-page":"4101","DOI":"10.1158\/1078-0432.CCR-21-0412","volume":"27","author":"JS Jolissaint","year":"2021","unstructured":"Jolissaint JS, Soares KC, Seier KP, et al. Intrahepatic cholangiocarcinoma with lymph node metastasis: treatment-related outcomes and the role of tumor genomics in patient selection. Clin Cancer Res. 2021;27(14):4101\u20138.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"11439_CR29","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1159\/000512967","volume":"99","author":"H Pietge","year":"2021","unstructured":"Pietge H, S\u00e1nchez-Vel\u00e1zquez P, Akhoundova D, et al. Combination of HAI-FUDR and systemic gemcitabine and cisplatin in unresectable cholangiocarcinoma: a dose finding single center study. Oncology. 2021;99(5):300\u20139.","journal-title":"Oncology."},{"issue":"9","key":"11439_CR30","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1093\/annonc\/mdp029","volume":"20","author":"WR Jarnagin","year":"2009","unstructured":"Jarnagin WR, Schwartz LH, Gultekin DH, et al. Regional chemotherapy for unresectable primary liver cancer: results of a phase II clinical trial and assessment of DCE-MRI as a biomarker of survival. Ann Oncol. 2009;20(9):1589\u201395.","journal-title":"Ann Oncol."},{"issue":"3\u20134","key":"11439_CR31","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1159\/000324704","volume":"80","author":"NE Kemeny","year":"2011","unstructured":"Kemeny NE, Schwartz L, G\u00f6nen M, et al. Treating primary liver cancer with hepatic arterial infusion of floxuridine and dexamethasone: does the addition of systemic bevacizumab improve results? Oncology. 2011;80(3\u20134):153\u20139.","journal-title":"Oncology."},{"issue":"1","key":"11439_CR32","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.ejso.2014.09.007","volume":"41","author":"DP Al-Adra","year":"2015","unstructured":"Al-Adra DP, Gill RS, Axford SJ, Shi X, Kneteman N, Liau SS. Treatment of unresectable intrahepatic cholangiocarcinoma with yttrium-90 radioembolization: a systematic review and pooled analysis. Eur J Surg Oncol. 2015;41(1):120\u20137.","journal-title":"Eur J Surg Oncol."},{"issue":"2","key":"11439_CR33","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1002\/jso.23781","volume":"111","author":"LM Boehm","year":"2015","unstructured":"Boehm LM, Jayakrishnan TT, Miura JT, et al. Comparative effectiveness of hepatic artery based therapies for unresectable intrahepatic cholangiocarcinoma. J Surg Oncol. 2015;111(2):213\u201320.","journal-title":"J Surg Oncol."},{"key":"11439_CR34","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.2147\/OTT.S93629","volume":"10","author":"S Buettner","year":"2017","unstructured":"Buettner S, van Vugt JL, IJzermans JN, Groot Koerkamp B. Intrahepatic cholangiocarcinoma: current perspectives. Onco Targets Ther. 2017;10:1131\u201342.","journal-title":"Onco Targets Ther."},{"issue":"7","key":"11439_CR35","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/j.jvir.2020.02.008","volume":"31","author":"S Buettner","year":"2020","unstructured":"Buettner S, Braat AJAT, Margonis GA, et al. Yttrium-90 radioembolization in intrahepatic cholangiocarcinoma: a multicenter retrospective analysis. J Vasc Interv Radiol. 2020;31(7):1035-1043.e2.","journal-title":"J Vasc Interv Radiol."},{"issue":"1","key":"11439_CR36","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1001\/jamaoncol.2019.3702","volume":"6","author":"J Edeline","year":"2019","unstructured":"Edeline J, Touchefeu Y, Guiu B, et al. Radioembolization plus chemotherapy for first-line treatment of locally advanced intrahepatic cholangiocarcinoma: a phase 2 clinical trial. JAMA Oncol. 2019;6(1):51\u20139.","journal-title":"JAMA Oncol."},{"issue":"5","key":"11439_CR37","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1200\/JCO.2015.64.2710","volume":"34","author":"TS Hong","year":"2016","unstructured":"Hong TS, Wo JY, Yeap BY, et al. Multi-institutional phase II study of high-dose hypofractionated proton beam therapy in patients with localized, unresectable hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol. 2016;34(5):460\u20138.","journal-title":"J Clin Oncol."},{"issue":"2","key":"11439_CR38","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.jhep.2019.10.009","volume":"72","author":"RK Kelley","year":"2020","unstructured":"Kelley RK, Bridgewater J, Gores GJ, Zhu AX. Systemic therapies for intrahepatic cholangiocarcinoma. J Hepatol. 2020;72(2):353\u201363.","journal-title":"J Hepatol."},{"issue":"4","key":"11439_CR39","doi-asserted-by":"publisher","first-page":"751","DOI":"10.21037\/jgo.2019.03.10","volume":"10","author":"AN Boscoe","year":"2019","unstructured":"Boscoe AN, Rolland C, Kelley RK. Frequency and prognostic significance of isocitrate dehydrogenase 1 mutations in cholangiocarcinoma: a systematic literature review. J Gastrointest Oncol. 2019;10(4):751\u201365.","journal-title":"J Gastrointest Oncol."},{"issue":"4","key":"11439_CR40","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1002\/hep.26890","volume":"59","author":"Y Arai","year":"2014","unstructured":"Arai Y, Totoki Y, Hosoda F, et al. Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma. Hepatology. 2014;59(4):1427\u201334.","journal-title":"Hepatology."},{"issue":"6","key":"11439_CR41","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/S1470-2045(20)30157-1","volume":"21","author":"GK Abou-Alfa","year":"2020","unstructured":"Abou-Alfa GK, Macarulla T, Javle MM, et al. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020;21(6):796\u2013807.","journal-title":"Lancet Oncol."},{"issue":"3_suppl","key":"11439_CR42","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1200\/JCO.2021.39.3_suppl.266","volume":"39","author":"AX Zhu","year":"2021","unstructured":"Zhu AX, Macarulla T, Javle MM, et al. Final results from ClarIDHy, a global, phase III, randomized, double-blind study of ivosidenib (IVO) versus placebo (PBO) in patients (pts) with previously treated cholangiocarcinoma (CCA) and an isocitrate dehydrogenase 1 (IDH1) mutation. J Clin Oncol. 2021;39(3_suppl):266.","journal-title":"J Clin Oncol"},{"issue":"3","key":"11439_CR43","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1200\/JCO.2017.75.5009","volume":"36","author":"M Javle","year":"2018","unstructured":"Javle M, Lowery M, Shroff RT, et al. Phase II study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma. J Clin Oncol. 2018;36(3):276\u201382.","journal-title":"J Clin Oncol."},{"issue":"30","key":"11439_CR44","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.2217\/fon-2020-0429","volume":"16","author":"TS Bekaii-Saab","year":"2020","unstructured":"Bekaii-Saab TS, Valle JW, Van Cutsem E, et al. FIGHT-302: First-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements. Future Oncol. 2020;16(30):2385\u201399.","journal-title":"Future Oncol."},{"issue":"10272","key":"11439_CR45","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/S0140-6736(21)00153-7","volume":"397","author":"JW Valle","year":"2021","unstructured":"Valle JW, Kelley RK, Nervi B, Oh DY, Zhu AX. Biliary tract cancer. Lancet. 2021;397(10272):428\u201344.","journal-title":"Lancet."},{"issue":"6349","key":"11439_CR46","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1126\/science.aan6733","volume":"357","author":"DT Le","year":"2017","unstructured":"Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357(6349):409\u201313.","journal-title":"Science."},{"issue":"9","key":"11439_CR47","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","volume":"17","author":"JM Banales","year":"2020","unstructured":"Banales JM, Marin JJG, Lamarca A, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020;17(9):557\u201388.","journal-title":"Nat Rev Gastroenterol Hepatol."},{"issue":"4","key":"11439_CR48","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/j.jhep.2021.04.004","volume":"75","author":"M Vithayathil","year":"2021","unstructured":"Vithayathil M, Bridegwater J, Khan SA. Medical therapies for intra-hepatic cholangiocarcinoma. J Hepatol. 2021;75(4):981\u20133.","journal-title":"J Hepatol."},{"issue":"1","key":"11439_CR49","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jamcollsurg.2005.03.019","volume":"201","author":"PJ Allen","year":"2005","unstructured":"Allen PJ, Nissan A, Picon AI, et al. Technical complications and durability of hepatic artery infusion pumps for unresectable colorectal liver metastases: an institutional experience of 544 consecutive cases. J Am Coll Surg. 2005;201(1):57\u201365.","journal-title":"J Am Coll Surg."},{"key":"11439_CR50","doi-asserted-by":"crossref","unstructured":"Netherlands Trial Register. Hepatic arterial infusion pump chemotherapy in patients with unresectable intrahepatic cholangiocarcinoma. https:\/\/www.trialregister.nl\/trial\/8234. Updated 2019. Accessed December 10, 2021.","DOI":"10.3390\/jcm10122552"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-022-11439-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-022-11439-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-022-11439-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,6]],"date-time":"2022-08-06T14:03:06Z","timestamp":1659794586000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-022-11439-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,16]]},"references-count":50,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["11439"],"URL":"https:\/\/doi.org\/10.1245\/s10434-022-11439-x","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,16]]},"assertion":[{"value":"18 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}